Frontiers in Oncology (Jun 2020)
Prostate Cancer Theranostics - An Overview
- Diane Abou,
- Diane Abou,
- Diane Abou,
- Nadia Benabdallah,
- Nadia Benabdallah,
- Wen Jiang,
- Wen Jiang,
- Lu Peng,
- Lu Peng,
- Lu Peng,
- Hanwen Zhang,
- Hanwen Zhang,
- Alexandria Villmer,
- Alexandria Villmer,
- Mark S. Longtine,
- Daniel L. J. Thorek,
- Daniel L. J. Thorek,
- Daniel L. J. Thorek,
- Daniel L. J. Thorek
Affiliations
- Diane Abou
- Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
- Diane Abou
- Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, United States
- Diane Abou
- Radiology Cyclotron Facility, Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, United States
- Nadia Benabdallah
- Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
- Nadia Benabdallah
- Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, United States
- Wen Jiang
- Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, United States
- Wen Jiang
- Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, United States
- Lu Peng
- Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
- Lu Peng
- Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, United States
- Lu Peng
- Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States
- Hanwen Zhang
- Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
- Hanwen Zhang
- Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, United States
- Alexandria Villmer
- Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
- Alexandria Villmer
- Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, United States
- Mark S. Longtine
- Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
- Daniel L. J. Thorek
- Department of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States
- Daniel L. J. Thorek
- Program in Quantitative Molecular Therapeutics, Washington University School of Medicine, St. Louis, MO, United States
- Daniel L. J. Thorek
- Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States
- Daniel L. J. Thorek
- Oncologic Imaging Program, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States
- DOI
- https://doi.org/10.3389/fonc.2020.00884
- Journal volume & issue
-
Vol. 10
Abstract
Metastatic prostate cancer is incurable, and novel methods to detect the disease earlier and to direct definitive treatment are needed. Molecularly specific tools to localize diagnostic and cytotoxic radionuclide payloads to cancer cells and the surrounding microenvironment are recognized as a critical component of new approaches to combat this disease. The implementation of theranostic approaches to characterize and personalize patient management is beginning to be realized for prostate cancer patients. This review article summarized clinically translated approaches to detect, characterize, and treat disease in this rapidly expanding field.
Keywords
